Bright Minds (DRUG) analyst forecast and price target
Analyst forecast
Consensus of 8 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Wolfe Research | Initiated Coverage | Outperform | $150.00 | Oct 15, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $145.00 | Aug 19, 2026 |
| BTIG | Maintained | Buy | $147.00 | Aug 17, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $145.00 | Jun 1, 2026 |
| Piper Sandler | Maintained | Overweight | $220.00 from $190.00 | May 20, 2026 |
| Jefferies | Initiated Coverage | Buy | $145.00 | Apr 13, 2026 |
| BTIG | Maintained | Buy | $147.00 | Mar 30, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $145.00 from $115.00 | Mar 4, 2026 |
| BTIG | Maintained | Buy | $147.00 | Feb 17, 2026 |
| BTIG | Maintained | Buy | $147.00 from $72.00 | Jan 7, 2026 |
| BTIG | Maintained | Buy | $147.00 from $72.00 | Jan 6, 2026 |
| Chardan Capital | Maintained | Buy | $80.00 | Jan 2, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $115.00 | Dec 30, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $85.00 | Sep 15, 2025 |
| BTIG | Initiated Coverage | Buy | $72.00 | Sep 8, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $85.00 | Aug 19, 2025 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | — | Jul 2, 2025 |
| Chardan Capital | Maintained | Buy | $80.00 | May 21, 2025 |
| TD Cowen | Initiated Coverage | Buy | — | May 13, 2025 |
| Chardan Capital | Initiated Coverage | Buy | $80.00 | May 7, 2025 |
Frequently asked questions
What is the price target for DRUG stock?
The average 12-month analyst price target for Bright Minds (DRUG) is $147.33, with a high estimate of $150.00 and a low of $145.00, across 3 analysts.
Is DRUG a buy, sell, or hold?
Analysts covering Bright Minds currently average a Buy rating: 8 buy, 0 hold and 0 sell, from 8 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for DRUG?
The average price target of $147.33 implies 171.78% upside from the last price of $54.21.
What is the latest analyst rating on DRUG?
On Oct 15, 2026, Wolfe Research initiated coverage of Bright Minds at Outperform with a price target of $150.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.